Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

BACKGROUND: Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. As a precautionary measure, many clinical studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Madduri, D., Parekh, S., Campbell, T. B., Neumann, F., Petrocca, F., Jagannath, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894235/
https://www.ncbi.nlm.nih.gov/pubmed/33608053
http://dx.doi.org/10.1186/s13256-020-02598-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894235/
https://www.ncbi.nlm.nih.gov/pubmed/33608053
http://dx.doi.org/10.1186/s13256-020-02598-0

Ejemplares similares